Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions / 医学前沿
Frontiers of Medicine
;
(4): 18-42, 2023.
Artículo
en Inglés
| WPRIM
| ID: wpr-971635
ABSTRACT
With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC), expanding the targeted therapeutic options improved the survival and safety. However, responses to these agents are commonly temporary and incomplete. Moreover, even patients with the same oncogenic driver gene can respond diversely to the same agent. Furthermore, the therapeutic role of immune-checkpoint inhibitors (ICIs) in oncogene-driven NSCLC remains unclear. Therefore, this review aimed to classify the management of NSCLC with driver mutations based on the gene subtype, concomitant mutation, and dynamic alternation. Then, we provide an overview of the resistant mechanism of target therapy occurring in targeted alternations ("target-dependent resistance") and in the parallel and downstream pathways ("target-independent resistance"). Thirdly, we discuss the effectiveness of ICIs for NSCLC with driver mutations and the combined therapeutic approaches that might reverse the immunosuppressive tumor immune microenvironment. Finally, we listed the emerging treatment strategies for the new oncogenic alternations, and proposed the perspective of NSCLC with driver mutations. This review will guide clinicians to design tailored treatments for NSCLC with driver mutations.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Microambiente Tumoral
/
Neoplasias Pulmonares
/
Mutación
Límite:
Humanos
Idioma:
Inglés
Revista:
Frontiers of Medicine
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS